Derek Lowe

  • Opinion

    Column: In the pipeline

    30 March 2011

    'Natural products are back!' is a headline Derek Lowe has seen several times before

  • Opinion

    Column: In the pipeline

    24 February 2011

    Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations

  • Opinion

    Column: In the pipeline

    31 January 2011

    Enzymes have been giving chemists inferiority complexes since day one, says Derek Lowe. But there's no denying their potential

  • Opinion

    Column: In the pipeline

    5 January 2011

    Some medicinal chemists can't get enough fluorines in their molecules. Derek Lowe explains the love-hate relationship

  • Opinion

    Column: In the pipeline

    29 November 2010

    Who's that asleep at the back? Don't be too quick to blame yourself when tedious talks and soporific seminars fail to inspire, says Derek Lowe

  • Opinion

    Column: In the pipeline

    28 October 2010

    Should companies focus on big markets and the blockbuster dream? The more modern approaches are not without risks, says Derek Lowe

  • Opinion

    Column: In the pipeline

    28 September 2010

    Derek Lowe investigates the comeback combinatorial chemistry has made in the field of drug discovery

  • Opinion

    Column: In the pipeline

    27 August 2010

    Derek Lowe considers the quandaries of living in the age of the kinase

  • Opinion

    Column: In the pipeline

    30 July 2010

    Derek Lowe reminisces about lost laboratory techniques and wonders which will be next to go

  • Opinion

    Column: In the pipeline

    25 June 2010

    Derek Lowe ponders the possibility of phosphatase inhibitors